Yubo International Biotech Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Yubo International Biotech Limited (MAGAA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Yubo International Biotech Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 108,274M combined for tracked competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $0.03M compares with $1.30M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Yubo International Biotech Limited vs. its Competitors, Q2 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Yubo International Biotech Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Yubo International Biotech Limited | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Yubo International Biotech Limited's competitor groups requires a Commercial License.
Yubo International Biotech Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Yubo International Biotech Limited | - | - | - | No |
| Competitors combined (7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MAGAA Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Biogen Inc | 282.9% | Outperformed |
| 2 | Amgen Inc | 282.9% | Outperformed |
| 3 | Vertex Pharmaceuticals Inc | 282.9% | Outperformed |
| 4 | Gilead Sciences Inc | 282.9% | Outperformed |
| 5 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Yubo International Biotech Limited's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Yubo International Biotech Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Yubo International Biotech Limited | 199.39 | 0.37 |
| Amgen Inc | 227,217.92 | 38,095.00 |
| Gilead Sciences Inc | 188,277.21 | 30,457.00 |
| Vertex Pharmaceuticals Inc | 133,826.88 | 12,587.20 |
| Regeneron Pharmaceuticals Inc | 79,007.10 | 15,534.70 |
| Biogen Inc | 33,767.68 | 9,937.40 |
| SUBTOTAL | 674,761.41 | 118,211.85 |
Sign in to see all competitors of Yubo International Biotech Limited.
Sources: Yubo International Biotech Limited's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Yubo International Biotech Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Yubo International Biotech Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Baxter International Inc | Medical Products and Therapies 47.57 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Yubo International Biotech Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Yubo International Biotech Limited | 199 | 26,431 | -73,903 |
| Amgen Inc | 227,218 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 188,277 | 1,791,588 | -190,588 |
| Vertex Pharmaceuticals Inc | 133,827 | 31,079,506 | 10,877,037 |
| Regeneron Pharmaceuticals Inc | 79,007 | 1,008,092 | 280,902 |
| Biogen Inc | 33,768 | 1,324,987 | 182,920 |
| PEERS TOTAL | 674,562 | 1,300,213 | 159,476 |
Sign in to see all peers for Yubo International Biotech Limited.
Yubo International Biotech Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Baxter International Inc | Non-US 1.44 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Yubo International Biotech Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Yubo International Biotech Limited's industry classification, broader than the peer set above. Market cap in millions of $.Yubo International Biotech Limited ranks #0 of 222 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 589, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 147,097 | 13.40 % |
| 2 | Medtronic Plc | 113,821 | 10.37 % |
| 3 | Stryker Corp | 107,775 | 9.82 % |
| 4 | 3m Company | 89,163 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 0 | Yubo International Biotech Limited | 199 | 0.00 % |
Market cap and industry share for the rest of Yubo International Biotech Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2020-12-03.
Yubo International Biotech Limited's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | -91.62 % | 479.84 % | - | - |
| Operating Margin | - | - | - | -123.99 % | -1,155.72 % | -197.58 % | - | - |
| Return on Invested Capital | 1.59 % | 1.53 % | 2.67 % | -62.19 % | 420.28 % | 52.14 % | 34.18 % | 21.40 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Yubo International Biotech Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 589 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Yubo International Biotech Limited's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Yubo International Biotech Limited's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Yubo International Biotech Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 36.6 points above the industry aggregate.
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Yubo International Biotech Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Yubo International Biotech Limited | 0.01 | 0.21 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Biogen Inc | - | 2.74 | 0.35 |
Sign in to see all peers for Yubo International Biotech Limited.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Yubo International Biotech Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Yubo International Biotech Limited | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Biogen Inc | Q1 2026 | +1.9 % | +32.8 % |
| PEERS TOTAL | +10.2 % | - |
Sign in to see all peers for Yubo International Biotech Limited.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Yubo International Biotech Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Yubo International Biotech Limited | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Biogen Inc | Q1 2026 | +5.0 % | +8.7 % |
Sign in to see all peers for Yubo International Biotech Limited.
Yubo International Biotech Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Yubo International Biotech Limited | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Biogen Inc | 4.71% | 5.23% | 7.54% |
Sign in to see all peers for Yubo International Biotech Limited.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Yubo International Biotech Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Yubo International Biotech Limited | 6.74 | 538.85 |
| Amgen Inc | 25.94 | 5.96 |
| Gilead Sciences Inc | - | 6.18 |
| Vertex Pharmaceuticals Inc | 30.58 | 10.63 |
| Regeneron Pharmaceuticals Inc | 18.46 | 5.09 |
| Biogen Inc | 24.41 | 3.40 |
| PEERS AVERAGE | 46.54 | 5.71 |
Sign in to see all peers for Yubo International Biotech Limited.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.